BCL2 and acute lymphoblastic leukemia: Since the “MYB addiction” of Ph+ ALL is not only due to CDK6 expression but also to other MYB-regulated genes such as BCL2, an alternative therapeutic strategy for Ph+ ALL is to combine a CDK6-selective PROTAC with a selective BCL2 antagonist like Venetoclax.